Recent Publications by Members of the Neutropenia, Infection & Myelosuppression Study Group

Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer. Rapoport B, Arani RB, Mathieson N, Krendyukov A. Future Oncol. 2019 Jun;15(18):2163-2174. Free Article.

Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF study. Aapro M, Krendyukov A, Höbel N, Gascon P. Eur J Cancer Care (Engl). 2019 Jul;28(4):e13034.

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study. Ludwig H, Bokemeyer C, Aapro M, Boccadoro M, Gascón P, Denhaerynck K, Krendyukov A, Abraham I, MacDonald K. Future Oncol. 2019 Mar;15(8):897-907. Free Article.

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study. Ludwig H, Gascón P, Bokemeyer C, Aapro M, Boccadoro M, Denhaerynck K, Krendyukov A, MacDonald K, Abraham I. Support Care Cancer. 2019 Jun;27(6):2301-2312.

Development of pediatric oncology supportive care indicators: Evaluation of febrile neutropenia care in the north of the Netherlands. Ten Berg S, Loeffen EAH, van de Wetering MD, Martens DHJ, van Ede CM, Kremer LCM, Tissing WJE. Pediatr Blood Cancer. 2019 Feb;66(2):e27504.

Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study. Rapoport BL, Aapro M, Paesmans M, van Eeden R, Smit T, Krendyukov A, Klastersky J. BMC Cancer. 2018 Sep 24;18(1):917. Free PMC Article.

Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia. van der Galiën HT, Loeffen EAH, Miedema KGE, Tissing WJE. Support Care Cancer. 2018 Nov;26(11):3819-3826. Free PMC Article.

Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, Kawakami K. Jpn J Clin Oncol. 2018 May 1;48(5):410-416.

Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia. Cupp J, Culakova E, Poniewierski MS, Dale DC, Lyman GH, Crawford J. Clin Lung Cancer. 2018 Mar;19(2):e163-e169. Review.

MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis. Gascón P, Krendyukov A, Höbel N, Aapro M. Eur J Haematol. 2018 Mar;100(3):241-246. 

Biosimilars in oncology: much ado about nothing? Aapro M. Ann Oncol. 2018 Jan 1;29(1):25-26. 

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V. Support Care Cancer. 2017 Nov;25(11):3295-3304.Review. Free PMC Article.

Supportive care for patients undergoing immunotherapy. Rapoport BL, van Eeden R, Sibaud V, Epstein JB, Klastersky J, Aapro M, Moodley D. Support Care Cancer. 2017 Oct;25(10):3017-3030.

Therapeutic Use of Filgrastim for Established Febrile Neutropenia Is Cost Effective Among Patients With Solid Tumors and Lymphomas. Wang XJ, Tong WX, Chan A. Clin Ther. 2017 Jun;39(6):1161-1170.

Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, Carlesse F er al. J Clin Oncol. 2017 Jun 20;35(18):2082-2094. 

The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas. Wang XJ, Goh DYT, Dorajoo SR, Chan A. Support Care Cancer. 2017 Sep;25(9):2815-2822.

Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. Bokemeyer C, Gascón P, Aapro M, Ludwig H, Boccadoro M, Denhaerynck K et al. Support Care Cancer. 2017 Jun;25(6):1819-1828.

Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions. Wang XJ, Chan A. Curr Oncol Rep. 2017 Mar;19(3):20. Review.

A randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. Tamura K, Inoue K, Masuda N, Takao S, Kashiwaba M, Tokuda Y, Iwata H, Yamamoto N, Aogi K, Saeki T, Nakayama T, Sato N, Toyama T, Ishida T, Arioka H, Saito M, Ohno S, Yamauchi H, Yamada K, Watanabe J, Ishiguro H, Fujiwara Y. Cancer Sci. 2017 Mar 3. doi: 10.1111/cas.13221. [Epub ahead of print]

Phase I study of pazopanib plus TH-302 in advanced solid tumors. Riedel RF, Meadows KL, Lee PH, Morse MA, Uronis HE, Blobe GC, George DJ, Crawford J, Niedzwiecki D, Rushing CN, Arrowood CC, Hurwitz HI. Cancer Chemother Pharmacol. 2017 Mar;79(3):611-619.

Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors. Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela J, Antonio M, Font C, Biosca M, Ramchandani A, Martinez-Garcia J, Hernando J, Espinosa J, de Castro EM, Ghanem I, Beato C, Blasco A, Garrido M, Mondéjar R, Arcusa MÁ, Aragón I, Manzano A, Sevillano E, Castañón E, Ayala F; Supportive Care Working Group of the Spanish Society of Medical Oncology (SEOM).. Clin Transl Oncol. 2017 Mar;19(3):386-395.

Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. Bokemeyer C, Gascón P, Aapro M, Ludwig H, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, Abraham I, MacDonald K. Support Care Cancer. 2017 Jan 22. [Epub ahead of print]

Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study). Aapro M, Bokemeyer C, Ludwig H, Gascón P, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, MacDonald K, Abraham I. J Geriatr Oncol. 2016 Nov 6. pii: S1879-4068(16)30118-7. [Epub ahead of print]

Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J; ESMO Guidelines Committee. Ann Oncol. 2016 Sep;27(suppl 5):v111-v118.

Psychometric Properties of the Functional Assessment of Cancer Therapy-Neutropenia in Asian Cancer Patients With Chemotherapy-Induced Neutropenia. Wang XJ, Wong CM, Chan A. J Pain Symptom Manage. 2016 Sep;52(3):428-36.

Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer. Phillips RS, Bhuller K, Sung L, Ammann RA, Tissing WJ, Lehrnbecher T, Stewart LA; PICNICC Collaboration. Eur J Cancer. 2016 Sep;64:101-6.

A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. Kubo K, Miyazaki Y, Murayama T, Shimazaki R, Usui N, Urabe A, Hotta T, Tamura K. Br J Haematol. 2016 Aug;174(4):563-70.

Use of procalcitonin in clinical oncology: a literature review. Sbrana A, Torchio M, Comolli G, Antonuzzo A, Danova M; Italian Network for Supportive Care in Oncology (NICSO). New Microbiol. 2016 Jul;39(3):174-180. Review.

The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC "Neutropenia, Infection and Myelosuppression" Study Group during the MASCC annual meeting held in Berlin on 27-29 June 2013. Rapoport B, Klastersky J, Raftopoulos H, Freifeld A, Aoun M, Zinner SH, Rolston KV. Support Care Cancer. 2016 Jul;24(7):2819-26.

A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. Fonseca PJ, Carmona-Bayonas A, García IM, Marcos R, Castañón E, Antonio M, Font C et al. Br J Cancer. 2016 May 24;114(11):1191-8.

Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. van Dalen EC, Mank A, Leclercq E, Mulder RL, Davies M, Kersten MJ, van de Wetering MD. Cochrane Database Syst Rev. 2016 Apr 24;4:CD006247. Review.

Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis. Phillips RS, Sung L, Amman RA, Riley RD, Castagnola E, Haeusler GM, Klaassen R, Tissing WJ, Lehrnbecher T, Chisholm J, Hakim H, Ranasinghe N, Paesmans M, Hann IM, Stewart LA; PICNICC Collaboration.. Br J Cancer. 2016 Mar 15;114(6):623-30.

Very early discharge versus early discharge versus non-early discharge in children with cancer and febrile neutropenia. Loeffen EA, Te Poele EM, Tissing WJ, Boezen HM, de Bont ES. Cochrane Database Syst Rev. 2016 Feb 22;2:CD008382. Review.

Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy. Wang XJ, Tang T, Farid M, Quek R, Tao M, Lim ST, Wee HL, Chan A. PLoS One. 2016 Feb 12;11(2):e0148901.

Understanding the risk for infection in patients with neutropenia. Klastersky JA, Meert AP. Intensive Care Med. 2016 Feb;42(2):268-70.

Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma. Lyman GH, Crawford J, Tomita D, Whittaker S, Dale DC. Leuk Lymphoma. 2016 Feb;57(2):283-90.

Risk-adapted approach for fever and neutropenia in paediatric cancer patients--a national multicentre study. Miedema KG, Tissing WJ, Abbink FC, Ball LM, Michiels EM, van Vliet MJ, de Vries WY, Kamps WA, Norbruis OF, Fiocco M, de Groot-Kruseman HA, van de Wetering MD, de Bont ES. Eur J Cancer. 2016 Jan;53:16-24.

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Gascón P, Aapro M, Ludwig H, Bokemeyer C, Boccadoro M, Turner M, Denhaerynck K, MacDonald K, Abraham I. Support Care Cancer. 2016 Feb 24(2):911-25. Erratum in: Support Care Cancer. 2015 Oct 19.

The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. Culakova E, Poniewierski MS, Wolff DA, Dale DC, Crawford J, Lyman GH. Springerplus. 2015 Aug 6;4:396.

Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk? Lyman GH, Dale DC, Legg JC, Abella E, Morrow PK, Whittaker S, Crawford J. Cancer Med. 2015 Aug;4(8):1153-60.

The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. Lyman GH, Reiner M, Morrow PK, Crawford J. Ann Oncol. 2015 Jul;26(7):1452-8.

A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas. Cheson BD, Crawford J. Br J Haematol. 2015 May;169(4):528-33.

Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review. Wang XJ, Lopez SE, Chan A. Crit Rev Oncol Hematol. 2015 May;94(2):201-12.

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y, Tamura K. Support Care Cancer. 2015 Apr;23(4):1137-43.

Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, et al. J Clin Oncol. 2015 Feb 10;33(5):465-71.

Prophylaxis of febrile neutropenia in adults receiving chemotherapy needs to be adapted to the risk. Georgala A, Klastersky JA. Expert Rev Hematol. 2015 Feb;8(1):115-21.

Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial. Nakane T, Tamura K, Hino M, Tamaki T, Yoshida I, Fukushima T et al; Japan Febrile Neutropenia Study Group.. J Infect Chemother. 2015 Jan;21(1):16-22.

Economic Burden of Febrile Neutropenia in Solid Tumor and Lymphoma Patients: An Observational Study in Singapore. Wang XJ, Wong M, Hsu LY, Chan A. Value Health. 2014 Nov;17(7):A734.

Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis. Funakoshi T, Suzuki M, Tamura K. Cancer Treat Rev. 2014 Dec;40(10):1221-9.

Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria. Klastersky J, Georgala A. Crit Rev Oncol Hematol. 2014 Dec;92(3):268-78.

Supportive care is a constant state of changing: we need to adjust for it. Klastersky JA. Curr Opin Oncol. 2014 Jul;26(4):371.

Adverse events of targeted therapies. Klastersky JA. Curr Opin Oncol. 2014 Jul;26(4):395-402.

Supportive care in cancer patients: a unifying concept. Klastersky JA. Curr Opin Oncol. 2013 Jul;25(4):341.

The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia. Klastersky J, Raftopoulos H, Rapoport B.  Support Care Cancer. 2013 Jun;21(6):1793-5.

The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Klastersky J, Paesmans M.  Support Care Cancer. 2013 May;21(5):1487-95.